EGFR and metastatic colorectal cancer: Monoclonal antibodies (MoAbs) against EGFR, such as cetuximab and panitumumab, have been developed and are able, by binding to EGFR extracellular domain, to prevent its activation, demonstrating high efficacy in metastatic colorectal cancer (mCRC), but only in a subgroup of patients [2].